The CHA2DS2-VASc Score for for Atrial Fibrillation Stroke Risk calculates stroke risk for patients with atrial fibrillation, possibly better than the CHADS2 score.

Unlike the original CHADS2 score, which was based on a retrospective Medicare registry, CHA 2 DS 2 -VASc prospectively included patients from multiple countries who were aged 18 years …

The CHADS2 score and its updated version, the CHA2DS2-VASc score, are clinical prediction rules for estimating the risk of stroke in people with non-rheumatic atrial fibrillation (AF), a common and serious heart arrhythmia associated with thromboembolic stroke.

Mar 17, 2025 · The CHA2DS2-VASc score allows you to calculate the stroke risk in a patient with atrial dibrillation.

It is used to determine whether or not treatment is required with anticoagulation therapy or antiplatelet therapy. A high CHADS 2 score corresponds to a greater risk of stroke, while a low CHADS 2 score corresponds to a lower risk of stroke.

The CHA2DS2-VASc score has been reported to have clinical value for predicting the severity of infarction and short to long-term clinical outcomes after AIS with and without AF in addition to its original purpose of assessing the risk of stroke in patients with AF.

The following vignettes are designed to demonstrate how CHA2DS2-VASc provides improved discrimination of stroke risk in AF compared with the CHADS2 score. Mrs. Washington is a 68-year-old woman with history of persistent AF currently managed with rhythm control on flecainide who has comorbid HTN.

CHA2DS2-VASc score 1,2: Clinical prediction rule for assessing the risk of stroke in patients with non-valvular atrial fibrillation. The result can be used to determine whether or not treatment is …

Statistical analysis identified patients with high CHA 2 DS 2 -VASc scores and defined the predictive value of individual parameters, or their combination, with regards to the outcomes of stroke and mortality.

We compared the performance of the widely used CHA 2 DS 2 -VASc and the recently developed R 2 CHADS 2 and ATRIA scores, for predicting thromboembolic (TE) event in either non-anticoagulated or anticoagulated patients with NVAF.